Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Endocrine Disorders
Published in: BMC Endocrine Disorders 1/2014

Open Access 01-12-2014 | Research article

Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas

Authors: Xin-Wei Qiao, Ling Qiu, Yuan-Jia Chen, Chang-Ting Meng, Zhao Sun, Chun-Mei Bai, Da-Chun Zhao, Tai-Ping Zhang, Yu-Pei Zhao, Yu-Li Song, Yu-Hong Wang, Jie Chen, Chong-Mei Lu

Published in: BMC Endocrine Disorders | Issue 1/2014

Login to get access

Abstract

Background

Pancreatic neuroendocrine tumors (PNETs) are a group of rare tumors. Chromogranin A (CgA) was considered as the most practical and useful serum tumor marker in PNET patients. But peripheral blood levels of CgA are not routinely tested in Chinese patients with PNETs. This study was to assess the diagnostic value of CgA in Chinese patients with PNETs especially in patients with insulinomas.

Methods

Eighty-nine patients with PNETs including 57 insulinomas and 32 non-insulinoma PNETs as well as 86 healthy participants were enrolled in this study between September 2003 and June 2013. Serum levels of CgA were measured by ELISA method. Expression of CgA protein was detected in 26 PNET tissues including 14 insulinomas by immunohistochemical staining.

Results

Serum levels of CgA in 89 PNET patients were significantly higher than that in healthy controls (P = 7.2 × 10−9). Serum levels of CgA in 57 patients with insulinomas (median 64.8 ng/ml, range 25–164) were slightly higher than the levels in healthy controls (median 53.4 ng/ml, range 39–94) but much lower than the levels in 32 patients with non-insulinoma PNETs (median 193 ng/ml, range 27–9021), P = 0.001. The serum CgA levels were reduced in 16 of 17 patients with insulinomas after tumor resection. ROC curve showed that CgA values at 60 ng/ml distinguished patients with insulinomas from healthy controls but its sensitivity and specificity were 66.7% and 73.3%, respectively. In contrast, CgA values at 74 ng/ml distinguished patients with non-insulinoma PNETs from healthy controls, and the sensitivity and specificity were 65.6% and 91.9%, respectively. Except for two insulinomas with negative staining of CgA, 12 insulinoma tissues showed positive staining of CgA.

Conclusion

CgA is a reliable serum diagnostic biomarker for PNETs but not for insulinomas.
Appendix
Available only for authorised users
Literature
1.
Rindi G, Wiedenmann B: Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol. 2012, 8 (1): 54-64.CrossRef
2.
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008, 26 (18): 3063-3072.CrossRefPubMed
3.
Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A: Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008, 9 (1): 61-72.CrossRefPubMed
4.
Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM: The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011, 40 (1): 1-18. viiCrossRefPubMed
5.
Oberg K, Knigge U, Kwekkeboom D, Perren A, Group EGW: Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012, 23 (Suppl 7): vii124-vii130.PubMed
6.
Oberg K, Eriksson B: Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005, 19 (5): 753-781.CrossRefPubMed
7.
Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M: Chromogranin A–biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 2010, 17 (9): 2427-2443.CrossRefPubMed
8.
Singh S, Law C: Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2012, 6 (3): 313-334.CrossRefPubMed
9.
Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, Krenning EP, Bouillon R, Lamberts SW: Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab. 1997, 82 (8): 2622-2628.PubMed
10.
Bashir S, Gibril F, Ojeaburu JV, Asgharian B, Entsuah LK, Ferraro G, Crafa P, Bordi C, Jensen RT: Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patients with gastrinomas. Aliment Pharmacol Ther. 2002, 16 (7): 1367-1382.CrossRefPubMed
11.
Abou-Saif A, Gibril F, Ojeaburu JV, Bashir S, Entsuah LK, Asgharian B, Jensen RT: Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer. 2003, 98 (2): 249-261.CrossRefPubMed
12.
Ardill JE, Erikkson B: The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocr Relat Cancer. 2003, 10 (4): 459-462.CrossRefPubMed
13.
Nehar D, Lombard-Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, Sassolas G, Borson-Chazot F: Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf). 2004, 60 (5): 644-652.CrossRef
14.
Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, Tomassetti P: Chromogranin A: is it a useful marker of neuroendocrine tumors?. J Clin Oncol. 2007, 25 (15): 1967-1973.CrossRefPubMed
15.
Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, De Braud F, Delle Fave G, Dogliotti L, Degli Uberti EC, Italian CromaNet Working Group: Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer. 2007, 14 (2): 473-482.CrossRefPubMed
16.
17.
Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM: The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011, 40 (1): 111-134. viiiCrossRefPubMed
18.
Oberg K: Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2011, 18 (Suppl 1): S17-S25.CrossRefPubMed
19.
Chou WC, Hung YS, Hsu JT, Chen JS, Lu CH, Hwang TL, Rau KM, Yeh KY, Chen TC, Sun CF: Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients. Neuroendocrinology. 2012, 95 (4): 344-350.CrossRefPubMed
20.
Walter T, Chardon L, Chopin-laly X, Raverot V, Caffin AG, Chayvialle JA, Scoazec JY, Lombard-Bohas C: Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?. Eur J Cancer. 2012, 48 (12): 1766-1773.CrossRefPubMed
21.
Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose KJ, Scherag A, Hahmann M, Muller HH, Barth P: Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol. 2008, 6 (7): 820-827.CrossRefPubMed
22.
Giovanella L, Marelli M, Ceriani L, Giardina G, Garancini S, Colombo L: Evaluation of chromogranin A expression in serum and tissues of breast cancer patients. Int J Biol Markers. 2001, 16 (4): 268-272.PubMed
23.
Ranno S, Motta M, Rampello E, Risino C, Bennati E, Malaguarnera M: The chromogranin-A (CgA) in prostate cancer. Arch Gerontol Geriatr. 2006, 43 (1): 117-126.CrossRefPubMed
24.
Sciarra A, Di Silverio F, Autran AM, Salciccia S, Gentilucci A, Alfarone A, Gentile V: Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma. Urol Int. 2009, 82 (2): 147-151.CrossRefPubMed
25.
Malaguarnera M, Vacante M, Fichera R, Cappellani A, Cristaldi E, Motta M: Chromogranin A (CgA) serum level as a marker of progression in hepatocellular carcinoma (HCC) of elderly patients. Arch Gerontol Geriatr. 2010, 51 (1): 81-85.CrossRefPubMed
26.
Biondi A, Malaguarnera G, Vacante M, Berretta M, D’Agata V, Malaguarnera M, Basile F, Drago F, Bertino G: Elevated serum levels of Chromogranin A in hepatocellular carcinoma. BMC Surg. 2012, 12 (Suppl 1): S7-CrossRefPubMedPubMedCentral
27.
Malaguarnera M, Cristaldi E, Cammalleri L, Colonna V, Lipari H, Capici A, Cavallaro A, Beretta M, Alessandria I, Luca S, Motta M: Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer. Arch Gerontol Geriatr. 2009, 48 (2): 213-217.CrossRefPubMed
28.
O’Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O’Connor J, Pape UF, Plockinger U, Mallorca Consensus Conference p, European Neuroendocrine Tumor S: ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers. Neuroendocrinology. 2009, 90 (2): 194-202.CrossRefPubMed
29.
Vinik AI, Woltering EA, Warner RR, Caplin M, O’Dorisio TM, Wiseman GA, Coppola D, Go VL, North American Neuroendocrine Tumor S: NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010, 39 (6): 713-734.CrossRefPubMed
30.
31.
32.
O’Dorisio TM, Krutzik SR, Woltering EA, Lindholm E, Joseph S, Gandolfi AE, Wang YZ, Boudreaux JP, Vinik AI, Go VL, Howe JR, Halfdanarson T, O'Dorisio MS, Mamikunian G: Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior. Pancreas. 2010, 39 (5): 611-616.CrossRefPubMed
33.
Chen YJ, Vortmeyer A, Zhuang Z, Huang S, Jensen RT: Loss of heterozygosity of chromosome 1q in gastrinomas: occurrence and prognostic significance. Cancer Res. 2003, 63 (4): 817-823.PubMed
34.
Yang YM, Liu TH, Chen YJ, Jiang WJ, Qian JM, Lu X, Gao J, Wu SF, Sang XT, Chen J: Chromosome 1q loss of heterozygosity frequently occurs in sporadic insulinomas and is associated with tumor malignancy. Int J Cancer. 2005, 117 (2): 234-240.CrossRefPubMed
35.
de Herder WW, Niederle B, Scoazec JY, Pauwels S, Kloppel G, Falconi M, Kwekkeboom DJ, Oberg K, Eriksson B, Wiedenmann B, Rindi G, O'Toole D, Ferone D, Frascati Consensus Conference, European Neuroendocrine Tumor Society: Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology. 2006, 84 (3): 183-188.CrossRefPubMed
36.
Mei M, Deng D, Liu TH, Sang XT, Lu X, Xiang HD, Zhou J, Wu H, Yang Y, Chen J, Lu CM, Chen YJ: Clinical implications of microsatellite instability and MLH1 gene inactivation in sporadic insulinomas. J Clin Endocrinol Metab. 2009, 94 (9): 3448-3457.CrossRefPubMed
37.
Zhao YP, Zhan HX, Zhang TP, Cong L, Dai MH, Liao Q, Cai LX: Surgical management of patients with insulinomas: Result of 292 cases in a single institution. J Surg Oncol. 2011, 103 (2): 169-174.CrossRefPubMed
38.
Wang YH, Lin Y, Xue L, Wang JH, Chen MH, Chen J: Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995–2012) in South China. BMC Endocr Disord. 2012, 12: 30-CrossRefPubMedPubMedCentral
39.
Liu B, Tang LH, Liu Z, Mei M, Yu R, Dhall D, Qiao XW, Zhang TP, Zhao YP, Liu TH, Xiao Y, Chen J, Xiang HD, Wu HY, Lu CM, Lv B, Zhou YR, Zhang Y, Deng DJ, Chen YJ: Alpha-Internexin: a novel biomarker for pancreatic neuroendocrine tumor aggressiveness. J Clin Endocrinol Metab. 2014, 99 (5): E786-E795.CrossRefPubMed
40.
Rindi G, Falconi M, Klersy C, Albarello L, Boninsegna L, Buchler MW, Capella C, Caplin M, Couvelard A, Doglioni C, Delle Fave G, Fischer L, Fusai G, de Herder WW, Jann H, Komminoth P, de Krijger RR, La Rosa S, Luong TV, Pape U, Perren A, Ruszniewski P, Scarpa A, Schmitt A, Solcia E, Wiedenmann B: TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst. 2012, 104 (10): 764-777.CrossRefPubMed
41.
Tomassetti P, Migliori M, Simoni P, Casadei R, De Iasio R, Corinaldesi R, Gullo L: Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol. 2001, 13 (1): 55-58.CrossRefPubMed
42.
Paik WH, Ryu JK, Song BJ, Kim J, Park JK, Kim YT, Yoon YB: Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm. J Korean Med Sci. 2013, 28 (5): 750-754.CrossRefPubMedPubMedCentral
43.
de Herder WW: Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007, 21 (1): 33-41.CrossRefPubMed
44.
Portela-Gomes GM, Grimelius L, Wilander E, Stridsberg M: Granins and granin-related peptides in neuroendocrine tumours. Regul Pept. 2010, 165 (1): 12-20.CrossRefPubMed
45.
Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB, Uk Ireland Neuroendocrine Tumour Society: Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012, 61 (1): 6-32.CrossRefPubMed
46.
Crippa S, Zerbi A, Boninsegna L, Capitanio V, Partelli S, Balzano G, Pederzoli P, Di Carlo V, Falconi M: Surgical management of insulinomas: short- and long-term outcomes after enucleations and pancreatic resections. Arch Surg. 2012, 147 (3): 261-266.CrossRefPubMed
47.
Molina R, Alvarez E, Aniel-Quiroga A, Borque M, Candas B, Leon A, Poyatos RM, Gelabert M: Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies. Tumour Biol. 2011, 32 (1): 13-22.CrossRefPubMed
48.
Ito T, Igarashi H, Jensen RT: Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors?. Pancreas. 2012, 41 (4): 505-507.CrossRefPubMedPubMedCentral
49.
Nolting S, Kuttner A, Lauseker M, Vogeser M, Haug A, Herrmann KA, Hoffmann JN, Spitzweg C, Goke B, Auernhammer CJ: Chromogranin a as serum marker for gastroenteropancreatic neuroendocrine tumors: a single center experience and literature review. Cancers. 2012, 4 (1): 141-155.CrossRefPubMedPubMedCentral
50.
Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ, Barchas JD: Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature. 1986, 324 (6096): 476-478.CrossRefPubMed
51.
Hertelendy ZI, Patel DG, Knittel JJ: Pancreastatin inhibits insulin secretion in RINm5F cells through obstruction of G-protein mediated, calcium-directed exocytosis. Cell Calcium. 1996, 19 (2): 125-132.CrossRefPubMed
52.
Gayen JR, Saberi M, Schenk S, Biswas N, Vaingankar SM, Cheung WW, Najjar SM, O’Connor DT, Bandyopadhyay G, Mahata SK: A novel pathway of insulin sensitivity in chromogranin A null mice: a crucial role for pancreastatin in glucose homeostasis. J Biol Chem. 2009, 284 (42): 28498-28509.CrossRefPubMedPubMedCentral
53.
Wiesli P, Uthoff H, Perren A, Pfammatter T, Zwimpfer C, Seiler H, Kindhauser R, Spinas GA, Schmid C: Are biochemical markers of neuroendocrine tumors coreleased with insulin following local calcium stimulation in patients with insulinomas?. Pancreas. 2011, 40 (7): 995-999.CrossRefPubMed
54.
Hosaka M, Watanabe T, Sakai Y, Uchiyama Y, Takeuchi T: Identification of a chromogranin A domain that mediates binding to secretogranin III and targeting to secretory granules in pituitary cells and pancreatic beta-cells. Mol Biol Cell. 2002, 13 (10): 3388-3399.CrossRefPubMedPubMedCentral
Metadata
Title
Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas
Authors
Xin-Wei Qiao
Ling Qiu
Yuan-Jia Chen
Chang-Ting Meng
Zhao Sun
Chun-Mei Bai
Da-Chun Zhao
Tai-Ping Zhang
Yu-Pei Zhao
Yu-Li Song
Yu-Hong Wang
Jie Chen
Chong-Mei Lu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2014
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/1472-6823-14-64

Other articles of this Issue 1/2014

BMC Endocrine Disorders 1/2014 Go to the issue

Research article

Identification of a novel pax8 gene sequence variant in four members of the same family: from congenital hypothyroidism with thyroid hypoplasia to mild subclinical hypothyroidism

Research article

Antihyperglycaemic treatment patterns, observed glycaemic control and determinants of treatment change among patients with type 2 diabetes in the United Kingdom primary care: a retrospective cohort study

Case report

Localized subacute thyroiditis presenting as a painful hot nodule

Research article

Association between metabolic syndrome and bone fractures: a meta-analysis of observational studies

Research article

Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus

Research article

The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits